Download Files:
Products Details
Product Description
– HYDAMTIQ is a PARP-1/2 inhibitor (IC50: 29-38 nM) with anticancer, anti-inflammatory, and ischemic protective effects. HYDAMTIQ inhibits pulmonary PARP activity, is effective against allergen-induced cough and dyspnea, and inhibits bronchial hyperresponsiveness to methacholine. HYDAMTIQ has broad-spectrum tumor suppressor effects, including ovarian and breast cancers, prostate and pancreatic tumors, and glioblastoma multiforme. HYDAMTIQ has demonstrated in vivo efficacy in animal models of cerebral ischemia, asthma, cancer, and more[1].
Web ID
– HY-155458
Shipping
– Room temperature
Molecular Formula
– C14H14N2O2S
References
– [1]Filipponi P et al. Continuous Flow Synthesis of the PARP-1/2 Inhibitor HYDAMTIQ: Synthetic Strategy, Optimization, and Green Metrics Evaluation[J]. Organic Process Research & Development, 2023.
CAS Number
– 1201832-32-7
Molecular Weight
– 274.34
SMILES
– O=C1NC2=C(C=C(CN(C)C)S2)C3=C(O)C=CC=C31
Clinical Information
– No Development Reported
Research Area
– Cancer; Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– PARP
Pathway
– Cell Cycle/DNA Damage;Epigenetics
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
